Reproducible, Reproducible, Reproducible
The same features of the Genpax analysis that mean that all strains of a species can be compared in one location with a common analysis...
top of page
Scaling new bioinformatic heights
Genpax analysis was created for the real-world problem from the bottom-up with scalability as an essential requirement. Scalability is a...
A resolution is coming
When strains are evolving at 1 to 10 nucleotides per year per genome, it is important to address as much of the genome sequence...
Why near-zero error matters
With some variation by species and genome size, most bacterial pathogens normally change at a rate of up to 10 SNP changes per genome per...
Easy adoption enables widescale use
While the costs and ease of sequencing have been falling, one common obstacle to adoption is the requirement for local genomics staff and...
Is AMR really a product of misuse and abuse by doctors?
It is repeatedly stated that we face a global challenge of antimicrobial resistance and catastrophic health and economic impacts, and...
Are we winning or losing the fight against TB?
At one level, the numbers look good, but if you look again, maybe not. Once upon a time, TB started out as something else, probably some...
Genomics and knowing the enemy.
As Sun Tzu famously said: ‘know your enemy’, or more correctly: ‘If you know the enemy and know yourself, you need not fear the result of...
What is the larger threat of hospital-associated infection?
COVID-19 is not the pandemic I was predicting. Year after year, for just over 10 years a new class of about 150 young, smart medical...
A hidden cost of COVID?
Life is full of initially hidden and unintended impacts and consequences; for something as huge and pervasive as COVID, no doubt they...
When will someone call laST orders?
Sequence Typing (ST) is a widely established and used methodology. It is most certainly better than its predecessors from the era before...
Genpax Poster: Limitations of sequence typing for isolate inclusion in outbreak investigations
Presented by Karolina Jackowska at the ESCMID Global Conference in Barcelona, 2024 Download the High Resolution PDF below:
Genpax CEO Julian Hardy Joins Cycling Challenge from Scotland to Rome for Motor Neuron Disease
Our CEO, Julian Hardy, is currently taking part in the 'All Roads Lead to Rome' cycling challenge in support of the 'My Name'5 Doddie...
Genpax named 2023 winners of the IET Excellence and Innovation Award for Health Technology
Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial...
bottom of page